OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The proteasome and proteasome inhibitors in multiple myeloma
Sara Gandolfi, Jacob P. Laubach, Teru Hideshima, et al.
Cancer and Metastasis Reviews (2017) Vol. 36, Iss. 4, pp. 561-584
Closed Access | Times Cited: 299
Sara Gandolfi, Jacob P. Laubach, Teru Hideshima, et al.
Cancer and Metastasis Reviews (2017) Vol. 36, Iss. 4, pp. 561-584
Closed Access | Times Cited: 299
Showing 1-25 of 299 citing articles:
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1164
Lei Zhong, Yueshan Li, Liang Xiong, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1164
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Silpa Narayanan, Chao‐Yun Cai, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2019) Vol. 48, pp. 100663-100663
Closed Access | Times Cited: 254
Silpa Narayanan, Chao‐Yun Cai, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2019) Vol. 48, pp. 100663-100663
Closed Access | Times Cited: 254
Proteasome Inhibitor Drugs
Lloyd D. Fricker
The Annual Review of Pharmacology and Toxicology (2019) Vol. 60, Iss. 1, pp. 457-476
Open Access | Times Cited: 231
Lloyd D. Fricker
The Annual Review of Pharmacology and Toxicology (2019) Vol. 60, Iss. 1, pp. 457-476
Open Access | Times Cited: 231
New therapeutic strategies to treat human cancers expressing mutant p53 proteins
Giovanni Blandino, Silvia Di Agostino
Journal of Experimental & Clinical Cancer Research (2018) Vol. 37, Iss. 1
Open Access | Times Cited: 188
Giovanni Blandino, Silvia Di Agostino
Journal of Experimental & Clinical Cancer Research (2018) Vol. 37, Iss. 1
Open Access | Times Cited: 188
Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
Alfonso Serrano del Valle, Alberto Anel, Javier Naval, et al.
Frontiers in Cell and Developmental Biology (2019) Vol. 7
Open Access | Times Cited: 177
Alfonso Serrano del Valle, Alberto Anel, Javier Naval, et al.
Frontiers in Cell and Developmental Biology (2019) Vol. 7
Open Access | Times Cited: 177
USP14: Structure, Function, and Target Inhibition
Feng Wang, Shuo Ning, Beiming Yu, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 76
Feng Wang, Shuo Ning, Beiming Yu, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 76
Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Parva Bhatt, Colin Kloock, Raymond L. Comenzo
Current Oncology (2023) Vol. 30, Iss. 2, pp. 2322-2347
Open Access | Times Cited: 46
Parva Bhatt, Colin Kloock, Raymond L. Comenzo
Current Oncology (2023) Vol. 30, Iss. 2, pp. 2322-2347
Open Access | Times Cited: 46
MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis
Xiaobin Wang, Yingqing Shi, Hua Shi, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 18
Xiaobin Wang, Yingqing Shi, Hua Shi, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 18
Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
Dandan Gao, Yang Lv, Fei Hong, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Dandan Gao, Yang Lv, Fei Hong, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 3
BNIP3L/NIX degradation leads to mitophagy deficiency in ischemic brains
Xiaoli Wu, Yanrong Zheng, Mengru Liu, et al.
Autophagy (2020) Vol. 17, Iss. 8, pp. 1934-1946
Open Access | Times Cited: 133
Xiaoli Wu, Yanrong Zheng, Mengru Liu, et al.
Autophagy (2020) Vol. 17, Iss. 8, pp. 1934-1946
Open Access | Times Cited: 133
Adapting to stress — chaperome networks in cancer
Suhasini Joshi, Tai Wang, Thaı́s L. S. Araujo, et al.
Nature reviews. Cancer (2018) Vol. 18, Iss. 9, pp. 562-575
Open Access | Times Cited: 132
Suhasini Joshi, Tai Wang, Thaı́s L. S. Araujo, et al.
Nature reviews. Cancer (2018) Vol. 18, Iss. 9, pp. 562-575
Open Access | Times Cited: 132
Multiple myeloma: the (r)evolution of current therapy and a glance into future
Annamaria Gullà, Kenneth C. Anderson
Haematologica (2020) Vol. 105, Iss. 10, pp. 2358-2367
Open Access | Times Cited: 115
Annamaria Gullà, Kenneth C. Anderson
Haematologica (2020) Vol. 105, Iss. 10, pp. 2358-2367
Open Access | Times Cited: 115
Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation
Annamaria Gullà, Eugenio Morelli, Mehmet Samur, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 5, pp. 468-483
Open Access | Times Cited: 102
Annamaria Gullà, Eugenio Morelli, Mehmet Samur, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 5, pp. 468-483
Open Access | Times Cited: 102
The safety of bortezomib for the treatment of multiple myeloma
Güldane Cengiz Seval, Meral Beksaç
Expert Opinion on Drug Safety (2018) Vol. 17, Iss. 9, pp. 953-962
Closed Access | Times Cited: 91
Güldane Cengiz Seval, Meral Beksaç
Expert Opinion on Drug Safety (2018) Vol. 17, Iss. 9, pp. 953-962
Closed Access | Times Cited: 91
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges
Grazia R. Tundo, Diego Sbardella, Anna Maria Santoro, et al.
Pharmacology & Therapeutics (2020) Vol. 213, pp. 107579-107579
Open Access | Times Cited: 88
Grazia R. Tundo, Diego Sbardella, Anna Maria Santoro, et al.
Pharmacology & Therapeutics (2020) Vol. 213, pp. 107579-107579
Open Access | Times Cited: 88
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures
Weiyan Cheng, Zhiheng Yang, Suhua Wang, et al.
European Journal of Medicinal Chemistry (2019) Vol. 164, pp. 615-639
Closed Access | Times Cited: 87
Weiyan Cheng, Zhiheng Yang, Suhua Wang, et al.
European Journal of Medicinal Chemistry (2019) Vol. 164, pp. 615-639
Closed Access | Times Cited: 87
Repurposing anticancer drugs for the management of COVID-19
Khalid El Bairi, Dario Trapani, Angelica Petrillo, et al.
European Journal of Cancer (2020) Vol. 141, pp. 40-61
Open Access | Times Cited: 83
Khalid El Bairi, Dario Trapani, Angelica Petrillo, et al.
European Journal of Cancer (2020) Vol. 141, pp. 40-61
Open Access | Times Cited: 83
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma
Eric K. Rowinsky, Agne Paner, Jesús G. Berdeja, et al.
Investigational New Drugs (2020) Vol. 38, Iss. 5, pp. 1448-1453
Open Access | Times Cited: 80
Eric K. Rowinsky, Agne Paner, Jesús G. Berdeja, et al.
Investigational New Drugs (2020) Vol. 38, Iss. 5, pp. 1448-1453
Open Access | Times Cited: 80
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Paul G. Richardson, Shaji Kumar, Tamás Masszi, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 22, pp. 2430-2442
Open Access | Times Cited: 79
Paul G. Richardson, Shaji Kumar, Tamás Masszi, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 22, pp. 2430-2442
Open Access | Times Cited: 79
Cancer Stemness: p53 at the Wheel
Dishari Ghatak, Damayanti Das Ghosh, Susanta Roychoudhury
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 61
Dishari Ghatak, Damayanti Das Ghosh, Susanta Roychoudhury
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 61
Giulio Donati, Bruno Amati
Molecular Oncology (2022) Vol. 16, Iss. 21, pp. 3828-3854
Open Access | Times Cited: 56
Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker
Anastasios I. Birmpilis, A. Paschalis, Apostolis Mourkakis, et al.
Cells (2022) Vol. 11, Iss. 9, pp. 1415-1415
Open Access | Times Cited: 54
Anastasios I. Birmpilis, A. Paschalis, Apostolis Mourkakis, et al.
Cells (2022) Vol. 11, Iss. 9, pp. 1415-1415
Open Access | Times Cited: 54
Protein kinase R is an innate immune sensor of proteotoxic stress via accumulation of cytoplasmic IL-24
Sophia Davidson, Chien‐Hsiung Yu, Annemarie Steiner, et al.
Science Immunology (2022) Vol. 7, Iss. 68
Open Access | Times Cited: 46
Sophia Davidson, Chien‐Hsiung Yu, Annemarie Steiner, et al.
Science Immunology (2022) Vol. 7, Iss. 68
Open Access | Times Cited: 46
Multiple Myeloma Therapy: Emerging Trends and Challenges
Danai Dima, Dongxu Jiang, Divya Jyoti Singh, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4082-4082
Open Access | Times Cited: 44
Danai Dima, Dongxu Jiang, Divya Jyoti Singh, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4082-4082
Open Access | Times Cited: 44
Ubiquitination and deubiquitination: Implications on cancer therapy
Gunjan Dagar, Rakesh Kumar, Kamlesh Yadav, et al.
Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms (2023) Vol. 1866, Iss. 4, pp. 194979-194979
Closed Access | Times Cited: 37
Gunjan Dagar, Rakesh Kumar, Kamlesh Yadav, et al.
Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms (2023) Vol. 1866, Iss. 4, pp. 194979-194979
Closed Access | Times Cited: 37
